Lung adenocarcinoma is the most common form of lung cancer, accounting for 60% of non-
small cell lung cancer (NSCLC) cases in Asian patients. Importantly, nearly half of these …

Tyrosine kinase inhibitors (TKIs) against EGFR and c-Met are initially effective when
administered individually or in combination to non-small cell lung cancer (NSCLC) patients …

Chemoresistance cells have features similar to cancer stem cells. Elimination of these cells
is an effective therapeutic strategy to clinically combat chemoresistance non-small cell lung …

There is a high death rate of lung cancer patients. Epidermal growth factor receptor tyrosine
kinase inhibitors (EGFR-TKIs) are effective in some lung adenocarcinoma patients with …

Despite the development of predictive biomarkers to shape treatment paradigms and
outcomes, de novo EGFR TKI resistance advanced non-small cell lung cancer (NSCLC) …

The refractory pulmonary adenocarcinoma is characterized by its metastasis and resistance
to cytotoxic agents. While the underlying molecular mechanism is unclear, the property of …

Background Although EGFR tyrosine kinase inhibitors (EGFR-TKIs) are beneficial to lung
adenocarcinoma patients with sensitive EGFR mutations, resistance to these inhibitors …

Lung cancer is still a main cause of cancer-related death worldwide. Non-small-cell lung
cancer (NSCLC) accounts for the majority of lung cancers, and gefitinib is an effective …

Epithelial to mesenchymal transition (EMT) is associated with resistance during EGFR
tyrosine kinase inhibitor (EGFR-TKI) therapy. Here, we investigated whether EMT is …

Background Acquired resistance to epidermal growth factor receptor tyrosine kinase
inhibitors (EGFR-TKIs) presents great challenges in the treatment of non-small cell lung …